featured
Antisense Oligonucleotide Tofersen for SOD1 ALS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
N. Engl. J. Med 2020 Jul 09;383(2)109-119, T Miller, M Cudkowicz, PJ Shaw, PM Andersen, N Atassi, RC Bucelli, A Genge, J Glass, S Ladha, AL Ludolph, NJ Maragakis, CJ McDermott, A Pestronk, J Ravits, F Salachas, R Trudell, P Van Damme, L Zinman, CF Bennett, R Lane, A Sandrock, H Runz, D Graham, H Houshyar, A McCampbell, I Nestorov, I Chang, M McNeill, L Fanning, S Fradette, TA FergusonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.